Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

PHASE1TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

February 22, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Supranuclear Palsy, Progressive
Interventions
DRUG

BIIB092

Same dose as corresponding CN002003 study panel.

Trial Locations (13)

10032

Columbia University Medical Center, New York

32607

University of Florida College of Medicine, Gainesville

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Inc., Boca Raton

33612

University of South Florida, Tampa

35294

The University of Alabama at Birmingham, Birmingham

60637

The University of Chicago Medical Center, Chicago

90024

David Geffen School of Medicine at UCLA, Los Angeles

92037

University of California San Diego, La Jolla

94158

University of California, San Francisco, Medical Center at Parnassus, San Francisco

55455-0341

University of Minnesota Medical School, Minneapolis

08901-1962

Robert Wood Johnson Medical School, New Brunswick

19104-4206

Hospital of the University of Pennsylvania, Philadelphia

75390-8830

The University of Texas Southwestern Medical Center, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY